The FDA introduced the most significant guideline in May 2024 (147), establishing criteria for the platform technology designation under Section 506K of the FD&C Act, aimed at improving drug development efficiency
Free shipment protection on every order Third-party tested CoA on file Discreet, tracked shipping Free shipping over $200 Members earn 5% back in store credit What is KLOW Blend GHK-CU/BPC-157/TB-500/KPV
Mitochondrial Support: Boosts mitochondrial function, which is essential for overall energy, cellular health, and longevity
13% for targeted formulas
As-needed protocol: Use DSIP only during periods of elevated stress or sleep difficulty Maintain for 2-4 weeks as needed Discontinue when sleep normalizes This conservative approach treats DSIP as a targeted intervention rather than ongoing supplementation
The medication is already in the cartridge at a known concentration